Novo Nordisk wins Europe OK for diabetes drug
LONDON (MarketWatch) — Novo Nordisk said the European Commission has granted marketing authorisation for Victoza, or liraglutide, for the treatment of type 2 diabetes in adults. Novo Nordisk will launch Victoza in the UK, Germany and Denmark during the summer and in other European markets during the second half of 2009 and throughout 2010. The launch won’t affect 2009 financial expectations, and the company will update its view on Aug. 6.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
